What is MannKind?
MannKind Corporation is a specialized biopharmaceutical entity dedicated to the development and commercialization of therapeutic solutions for endocrine and orphan lung diseases. The company's core portfolio includes Afrezza Inhalation Powder, a transformative inhaled insulin for glycemic control, and the V-Go wearable insulin delivery device. Furthermore, the company has expanded its reach into pulmonary health through the integration of Tyvaso DPI for pulmonary arterial hypertension. By focusing on patient-centric delivery systems, MannKind occupies a unique niche in the medical technology market, bridging the gap between complex pharmaceutical science and practical, daily patient management.
How much funding has MannKind raised?
MannKind has raised a total of $1.7B across 14 funding rounds:
Stock Offering
$36.2M
Stock Offering
$47.5M
Stock Offering
$61M
Stock Offering
$28M
Debt
$2M
Stock/Share Issuance
$500M
Stock/Share Issuance
$50M
Stock Issuance/Offering (2015): $36.2M, investors not publicly disclosed
Stock Issuance/Offering (2016): $47.5M, investors not publicly disclosed
Stock Issuance/Offering (2017): $61M, investors not publicly disclosed
Stock Issuance/Offering (2018): $28M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Stock/Share Issuance (2025): $500M, investors not publicly disclosed
Stock/Share Issuance (2026): $50M featuring Frazier Life Sciences Management
Key Investors in MannKind
Frazier Life Sciences Management
Frazier Life Sciences is a longstanding biotech investment firm that employs both venture and public strategies to partner with and build companies focused on developing novel therapeutics.
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation, focusing on immunology, rare diseases, and oncology.
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem.
What's next for MannKind?
With the recent infusion of capital, MannKind is well-positioned to accelerate its research and development initiatives while optimizing its commercial footprint. The strategic focus will likely shift toward expanding the adoption of its existing therapeutic suite and exploring new indications for its proprietary inhalation technology. As the company matures, the emphasis on operational efficiency and clinical excellence will be paramount in maintaining its competitive advantage. Investors and industry analysts will be closely monitoring the firm's ability to translate this financial momentum into sustained revenue growth and expanded market share within the highly regulated biopharmaceutical environment.
See full MannKind company page
